An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells

Bibliography

• Lopez RD, Waller EK, Lu PH, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother 2001;49(12):629-40
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174(1):139-49
   PubMed Web of Science ®Google Scholar
• Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987;138(8):2728-33
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21(13):1673-9
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153(4):1687-96
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008;20(7):841-8
   PubMed Web of Science ®Google Scholar
• Franceschetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009;37(5):616-28
   PubMed Web of Science ®Google Scholar
• Verneris MR, Ito M, Baker J, et al. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001;7(10):532-42
   PubMed Web of Science ®Google Scholar
• Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004;103(8):3065-72
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96(12):6879-84
   PubMed Web of Science ®Google Scholar
• Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62(21):6178-86
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin G, Guo ZQ, et al. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS ONE 2013;8(7):e69044
   PubMed Web of Science ®Google Scholar
• Pan K, Wang QJ, Liu Q, et al. The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumour Biol 2014;35(1):701-7
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Leuci V, et al. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 2013;19(16):4347-58
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Mesiano G, Gammaitoni L, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res 2013;74(1):1-11
   Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105-11
   PubMed Web of Science ®Google Scholar
• Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012;12(5):565-72
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441(7090):235-8
   PubMed Web of Science ®Google Scholar
• Lin G, Wang J, Lao X, et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother 2012;35(4):337-43
   PubMed Web of Science ®Google Scholar
• Zoll B, Lefterova P, Csipai M, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998;47(4):221-6
   PubMed Web of Science ®Google Scholar
• Helms MW, Prescher JA, Cao YA, et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010;59(9):1325-34
   PubMed Web of Science ®Google Scholar
• Rettinger E, Kuçi S, Naumann I, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012;14(1):91-103
   PubMed Web of Science ®Google Scholar
• Rettinger E, Meyer V, Kreyenberg H, et al. Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. Front Oncol 2012;2:32
   PubMedGoogle Scholar
• Tao Q, Chen T, Tao L, et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35. J Immunother 2013;36(9):462-7
   PubMed Web of Science ®Google Scholar
• Wei C, Wang W, Pang W, et al. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Cai C, Chen W, Miao D, et al. Toll-like receptor 4 is required for the cytotoxicity of cytokine-induced killer cells. Acta Haematol 2013;132(1):5-9
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhao MF, Rajbhandary S, et al. Effects of humanized interleukin 21 on anti-leukemic activity of cytokine induced killer cells and the mechanism. Zhonghua Xue Ye Xue Za Zhi 2012;33(10):823-8
   PubMedGoogle Scholar
• Rajbhandary S, Zhao MF, Zhao N, et al. Multiple Cytotoxic Factors Involved in IL-21 Enhanced Antitumor Function of CIK Cells Signaled through STAT-3 and STAT5b Pathways. Asian Pac J Cancer Prev 2013;14(10):5825-31
   PubMed Web of Science ®Google Scholar
• Yan Y, Xu Y, Zhao Y, et al. Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model. Tumour Biol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Yang Z, Zhang Q, Xu K, et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One 2012;7(9):e44802
   PubMed Web of Science ®Google Scholar
• Liu C, Suksanpaisan L, Chen YW, et al. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol 2013;41(6):508-17
   PubMed Web of Science ®Google Scholar
• Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14:324-33
   PubMed Web of Science ®Google Scholar
• Märten A, Ziske C, Schöttker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001;24(6):502-10
   PubMed Web of Science ®Google Scholar
• Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 2013;6(2):537-41
   PubMed Web of Science ®Google Scholar
• Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011;35(9):1136-42
   PubMed Web of Science ®Google Scholar
• Wang YF, Kunda PE, Lin JW, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol Rep 2013;29(5):1841-50
   PubMed Web of Science ®Google Scholar
• Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, et al. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3(+)CD56(+) subset through the co-culturing dendritic cells. PLoS One 2013;8(11):e78980
   PubMedGoogle Scholar
• Chen J, Huang X, Huang G, et al. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 2012;27(3):210-20
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang Y, Wang H, et al. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol 2013;139(8):1357-72
   PubMed Web of Science ®Google Scholar
• Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2013;62(1):65-73
   PubMed Web of Science ®Google Scholar
• Shi SB, Ma TH, Li CH, Tang XY. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012;98(3):314-19
   PubMed Web of Science ®Google Scholar
• Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Zhan HL, Gao X, Pu XY, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl) 2012;125(21):3771-7
   PubMed Web of Science ®Google Scholar
• Qiu Y, Xu MB, Yun MM, et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol 2011;17(48):5260-6
   PubMed Web of Science ®Google Scholar
• Qiu Y, Yun MM, Xu MB, et al. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol 2013;18(4):657-65
   PubMed Web of Science ®Google Scholar
• Du X, Jin R, Ning N, et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep 2012;28(5):1743-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Hou Y, Zhang J, et al. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett 2013;5(6):1826-32
   PubMed Web of Science ®Google Scholar
• Huang J, Li C, Wang Y, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol 2013;149(1):156-68
   PubMed Web of Science ®Google Scholar
• Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012;2012:238924
   PubMedGoogle Scholar
• Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 “super-stimulation”. Mol Ther 2013;21(12):2268-77
   PubMed Web of Science ®Google Scholar
• Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE 2013;8(6):e65757
   PubMed Web of Science ®Google Scholar
• Tao L, Huang G, Shi S, Chen L. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol 2014;31(1):777
   PubMed Web of Science ®Google Scholar
• Wang JP, Li W, Huang ZL, et al. Value of CIK in the treatment of TACE combined with RFA for HCC in long-term survival and prognostic analysis. Zhonghua Yi Xue Za Zhi 2012;92(43):3062-6
   PubMedGoogle Scholar
• Huang ZM, Li W, Li S, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013;36(5):287-93
   PubMed Web of Science ®Google Scholar
• Niu LZ, Li JL, Zeng JY, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013;19(22):3473-80
   PubMed Web of Science ®Google Scholar
• Yuanying Y, Lizhi N, Feng M, et al. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology 2013;67(2):235-40
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Liu Y, et al. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J Immunother 2014;37(1):43-50
   PubMed Web of Science ®Google Scholar
• Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012;61(12):2251-9
   PubMed Web of Science ®Google Scholar
• Zhao H, Fan Y, Li H, et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm 2013;28(4):303-9
   PubMed Web of Science ®Google Scholar
• Liu H, Song J, Yang Z, Zhang X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 2013;6(4):953-6
   PubMed Web of Science ®Google Scholar
• Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 2013;20(13):4305-11
   PubMed Web of Science ®Google Scholar
• Yu X, Zhao H, Liu L, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma. J Clin Immunol 2013. [Epub ahead of print]
   Google Scholar
• Li R, Wang C, Liu L, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012;61(11):2125-33
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang H, Li Y, et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother 2013;62(10):1629-35
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012;18(6):1751-9
   PubMed Web of Science ®Google Scholar
• Liang XF, Ma DC, Ding ZY, et al. Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study. Zhonghua Zhong Liu Za Zhi 2013;35(10):764-8
   PubMedGoogle Scholar
• Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137(2):305-10
   PubMed Web of Science ®Google Scholar